COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02851849
Recruitment Status : Completed
First Posted : August 2, 2016
Last Update Posted : January 12, 2018
Information provided by (Responsible Party):
Ligand Pharmaceuticals

Brief Summary:
The purpose of this study is to evaluate the change from baseline in hemoglobin A1c (HbA1c) during 12 weeks of treatment with 3 dose levels of LGD-6972 compared to placebo in subjects with Type 2 Diabetes Mellitus (T2DM)

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Drug: LGD-6972-5 mg Drug: LGD-6972-10 mg Drug: LGD-6972-15 mg Other: Placebo Phase 2

Detailed Description:

This will be a 12-week, randomized, double-blind, placebo-controlled, 4-arm, parallel group, multi-center study to evaluate the safety and efficacy of LGD-6972 in subjects with T2DM inadequately controlled on metformin monotherapy (a stable [≥12 weeks], daily dose of ≥1000mg at randomization). Subjects with T2DM will be treated with one of 3 dose levels of LGD-6972 (5 mg, 10 mg, or 15 mg) or placebo once daily (QD) for 12 weeks. Randomization will be stratified by HbAlc ≤8.5% or >8.5% at the Placebo Lead-in Visit.

Qualified subjects who require adjustment or stabilization of their metformin dose will participate in a run-in period of up to 12 additional weeks prior to randomization. Subjects will have the option to participate in an oral glucose tolerance test (OGTT) at baseline and end of treatment for assessment of exploratory endpoints.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 148 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety and Efficacy of LGD-6972 in Patients With Type 2 Diabetes Mellitus
Study Start Date : September 2016
Actual Primary Completion Date : June 2017
Actual Study Completion Date : June 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: LGD-6972-5 mg
5 mg LGD-6972 QD
Drug: LGD-6972-5 mg
5 mg LGD-6972 QD
Other Name: LGD-6972 sodium salt capsules

Active Comparator: LGD-6972-10 mg
10 mg LGD-6972 QD
Drug: LGD-6972-10 mg
10 mg LGD-6972 QD
Other Name: LGD-6972 sodium salt capsules

Active Comparator: LGD-6972-15 mg
15 mg LGD-6972 QD
Drug: LGD-6972-15 mg
15 mg LGD-6972 QD
Other Name: LGD-6972 sodium salt capsules

Placebo Comparator: Placebo
Placebo QD
Other: Placebo
Placebo QD

Primary Outcome Measures :
  1. Change from baseline in HbA1c [ Time Frame: 12 Weeks ]

Secondary Outcome Measures :
  1. Change from baseline in HbA1C [ Time Frame: Baseline to Weeks 2,4,8 ]
  2. Change from baseline in fasting glucose [ Time Frame: Baseline to Weeks 2,4,8 and 12 ]
  3. Change from baseline values for fasting glucagon [ Time Frame: Baseline to Weeks 2,4,8 and 12 ]
  4. Change from baseline values for fasting GLP-1 (total and active) [ Time Frame: Baseline to Weeks 2,4,8 and 12 ]
  5. Change from baseline values for fasting insulin [ Time Frame: Baseline to Weeks 2,4,8 and 12 ]
  6. Change from baseline values for fasting lipids (total, LDL, and HDL cholesterol and triglycerides) [ Time Frame: Baseline to Weeks 2,4,8, and 12 ]
  7. Change from baseline in blood pressure (systolic and diastolic) [ Time Frame: Baseline to Weeks 2,4,8, and 12 ]
  8. Change from baseline in body weight [ Time Frame: Baseline to Weeks 2,4,8 and 12 ]

Other Outcome Measures:
  1. Exploratory Objective - Change from baseline from an Oral Glucose Tolerance Test (area under the curve for glucose, glucagon, insulin, C-peptide, and total and active GLP-1) [ Time Frame: Baseline, 12 Weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Female subjects must be surgically sterile (hysterectomy or bilateral oophorectomy or bilateral tubal ligation), or naturally post-menopausal for at least 12 months and with a follicle stimulating hormone (FSH) level in the post-menopausal range (if not taking hormone replacement therapy)
  2. Male subjects must either have a vasectomy or agree that they and any female partners will use 2 acceptable forms of contraception, one of which must be a condom, until 30 days after the last dose of study drug. Other acceptable forms of contraception include hormonal contraceptives that have been at stable dose for 12 weeks prior to randomization, intrauterine device, Depo-Provera®, Norplant® System Implants, bilateral tubal ligation, bilateral oophorectomy, hysterectomy, and contraceptive sponge, foam, or jelly. Also, male subjects must not donate sperm during the study and for 30 days after the last dose of study drug
  3. Willing and able to provide written informed consent
  4. Diagnosis of T2DM according to American Diabetes Association criteria
  5. Currently on stable metformin or metformin extended-release therapy (unchanged dose [minimum daily dose of 1000 mg] for ≥12 weeks prior to screening)
  6. Subjects must have an HbA1c value of ≥7.0% to ≤10.5%
  7. Subjects must have a fasting plasma glucose of ≤260 mg/dL
  8. Subjects must have a body mass index (BMI) between 25 kg/m2 and 40 kg/m2, inclusive, and must weigh more than 45 kg

Exclusion Criteria:

  1. History of type 1 diabetes mellitus or history of diabetic ketoacidosis or persistent hypoglycemia or hypoglycemia unawareness
  2. Women of childbearing potential, lactating, or has a positive pregnancy test
  3. History or presence of alcoholism or drug abuse within 2 years prior to screening
  4. Unwilling to comply with study restrictions, including restrictions on strenuous exercise
  5. Presence of any of the following conditions: renal impairment (defined as history or estimated glomerular filtration rate at screening of <45 mL/min using the Modification of Diet in Renal Disease equation), diabetic proliferative retinopathy, severely symptomatic diabetic neuropathy requiring treatment, diabetic gastroparesis, active liver disease (other than asymptomatic nonalcoholic fatty liver disease), cirrhosis, symptomatic gall bladder disease, or pancreatitis
  6. Serum triglyceride level > 400 mg/dL at screening
  7. Liver transaminase levels (AST or ALT) >150% ULN, total bilirubin >2 ULN, or creatine kinase (CK) levels > 3 × ULN at screening
  8. History or evidence of clinically significant cardiovascular, pulmonary, renal, endocrine (other than T2DM), hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease or surgical intervention (eg, bariatric surgery) or allergic conditions (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
  9. Myocardial infarction, unstable angina, arterial revascularization, stroke, symptomatic peripheral artery disease, deep vein thrombosis, New York Heart Association Functional Class III or IV heart failure, or transient ischemic attack within 6 months prior to screening
  10. History of malignant hypertension or a recent history of uncontrolled high blood pressure or at screening has a seated systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg after at least a 5 minute rest. Blood pressure is determined as the mean of triplicate measurements collected at 2- minute intervals after the subject has been sitting quietly for at least 5 minutes. Therapy for hypertension (beta blockers excluded) that has been stable for at least 8 weeks prior to screening is permitted
  11. Arm size in excess of the maximum limit of the largest cuff provided with the study blood pressure monitor
  12. History of malignancy (except adequately treated basal or squamous cell skin cancer or cervical carcinoma in situ) within 5 years prior to screening
  13. History or evidence of QT prolongation or clinically significant QT prolongation (QTcF >450 msec) at screening, or other significant ECG findings at screening that may place the subject at increased risk by participating in the study
  14. Treatment with any type of insulin (injected or inhaled) for > 6 consecutive days within 6 months prior to screening or any insulin therapy within 12 weeks prior to screening
  15. Treated with peroxisome proliferator-activated receptor-gamma agonists (thiazolidinediones [TZDs]), incretin therapy (GLP-1 agonists). or amylin mimetics within 12 weeks prior to screening
  16. Taking any of the following prohibited medications

    • Antidepressants, antipsychotics, anti-epileptics, hormone replacement therapies (estrogen, progestin), testosterone therapies, and thyroid replacement medications that are not at a stable dose for at least 12 weeks prior to screening
    • Lipid-modifying medications and anti-hypertensive medications that have not been at a stable dose for at least 8 weeks prior to the Screening Visit (excluding bile acid sequestrants, ezetimibe, and beta blockers, which are prohibited
    • Over-the-counter herbal medications and supplement (aside from once daily multivitamins)
  17. Treatment with systemic corticosteroids, which must be discontinued at least 4 weeks prior to screening. Note: Inhaled, intraarticular, intranasal and topical corticosteroids are permitted
  18. Currently treated with weight-loss medications. These must be discontinued ≥12 weeks prior to screening
  19. History or evidence of intravenous illicit drug use, active hepatitis B virus (HBV), hepatitis C virus (HCV), and/or human immunodeficiency virus (HIV) infection
  20. Known hypersensitivity or idiosyncratic reaction to glucagon receptor (GCGR) antagonists or LGD-6972
  21. Participation in another interventional clinical trial within 30 days prior to dosing or treatment with an investigational product with 14 days or 5 half-lives of the Screening Visit (whichever is longer)
  22. Donated ≥ 450 mL of blood within 56 days of screening or has donated blood products within 30 days of screening
  23. Inability to comply with study procedures or to adhere to study-required restrictions

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02851849

Layout table for location information
United States, Alabama
Tuscumbia, Alabama, United States, 35674
United States, Arizona
Chandler, Arizona, United States, 85224
Surprise, Arizona, United States, 85374
United States, California
Huntington Park, California, United States, 90255
Los Angeles, California, United States, 90057
Montclair, California, United States, 91763
North Hollywood, California, United States, 91606
San Diego, California, United States, 92161
United States, Colorado
Denver, Colorado, United States, 80209
United States, Florida
Brooksville, Florida, United States, 34601
Miami, Florida, United States, 33014
Orlando, Florida, United States, 32804
Tampa, Florida, United States, 33607
United States, Illinois
Chicago, Illinois, United States, 60607
United States, Nevada
Las Vegas, Nevada, United States, 89119
United States, New Mexico
Albuquerque, New Mexico, United States, 87102
United States, New York
Hopewell Junction, New York, United States, 12533
United States, North Carolina
Durham, North Carolina, United States, 27710
Greensboro, North Carolina, United States, 27410
United States, Ohio
Franklin, Ohio, United States, 45005
Munroe Falls, Ohio, United States, 44262
United States, South Carolina
Summerville, South Carolina, United States, 29485
United States, Texas
Carrollton, Texas, United States, 75007
Dallas, Texas, United States, 75230
Houston, Texas, United States, 77036
Houston, Texas, United States, 77074
Houston, Texas, United States, 77099
Katy, Texas, United States, 77450
United States, Virginia
Manassas, Virginia, United States, 20110
Sponsors and Collaborators
Ligand Pharmaceuticals
Layout table for investigator information
Study Director: Keith Marschke, Ph.D. Ligand Pharmaceuticals
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ligand Pharmaceuticals Identifier: NCT02851849    
Other Study ID Numbers: L6972-04
First Posted: August 2, 2016    Key Record Dates
Last Update Posted: January 12, 2018
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases